

# Saudi Arabia

## COUNTRY GENERAL INFORMATION

Total population:	33 413 660
Gender F/M (%):	42.4 / 57.6
Population, age group <15 / ≥ 15 years (%):	25 / 75
Life expectancy at birth (F/M, years):	75 / 72
GDP (PPP int \$):	55 120
Income status:	High income
Number of 1 <sup>st</sup> sub-national administrative level divisions, name:	20, Region



## EPIDEMIOLOGY

	VL	ACL	ZCL	MCL
Endemicity status:	Endemic	Endemic	Endemic	Non endemic
Number of new cases (incidence):	2	123	798	0
Number of relapses: <sup>1</sup>	0	No data	No data	N/A
<b>Total number of cases:</b>	<b>2</b>	<b>123</b>	<b>798</b>	<b>0</b>
Imported cases (#, %):	1, 50%	No data	No data	No data
Gender distribution (% F):	0	No data	No data	N/A
Age group distribution (% , <5 / 5-14 / >14):	No data	No data	No data	N/A
Incidence rate (cases/10 000 population in endemic areas):	0.01	0.17	0.29	N/A
Number of endemic 1 <sup>st</sup> sub-national administrative level divisions:	1	5	14	N/A
Population at risk (% , # at risk / total population): <sup>2</sup>	5% 1 603 659/ 33 413 660	22% 7 326 214/ 33 413 660	84% 27 950 281/ 33 413 660	N/A
Was there any outbreak?	No	No	No	N/A
Number of new foci: <sup>3</sup>	0	0	0	N/A



## Monthly distribution of new cases (January-December)

2018	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	1	0	0	1	0	0	0	0	0	0	0	0
ACL	18	13	10	10	2	9	5	4	9	9	21	13
ZCL	110	83	68	48	42	49	72	65	50	72	38	101

N/A not applicable; VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL = zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis



## Number of new cases and Incidence rate/10 000 at the national level from 2003 to 2018




<sup>1</sup>Relapse in this country is defined for VL as: "A patient who discharged with initial cure and returned with clinical signs of VL and positive parasitology" and for CL as: "Recurrence of clinical signs after complete cure"

<sup>2</sup>Defined as: "Number of people living in 1st sub-national administrative level endemic areas"

<sup>3</sup>Defined as: "In this reporting period, an area at the 1st sub-national administrative level reporting cases for the first time ever"

## Disease distribution of new VL, ACL and ZCL at Regional level per 10 000 population (2018)



## CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	1978
Type of surveillance (CL / VL):	Integrated / Integrated
Is there a vector control programme?	Yes
Type of insecticide used for Indoor residual Spraying (IRS):	Deltamethrin, Lambdacyhalothrin, Etofenoprox
Year latest national guidelines (CL / VL):	2019 / No data
Is leishmaniasis notifiable (mandatory report)? (CL / VL):	No / Yes
Is there a reservoir host control programme?	No
Number of leishmaniasis health facilities (CL / VL):	No data / No data

## DIAGNOSIS

	VL	ACL	ZCL	MCL
Number of people screened actively for:	0	No data	No data	N/A
Number of people screened passively for:	No data	No data	No data	N/A
VL cases diagnosed by RDT (% , # RDT+ / new VL cases):	No data	N/A	N/A	N/A
Proportion of positive RDT (% , # RDT+ / total RDT):	No data	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% , # slides + / total cases):	100% (2/2)	No data	No data	N/A
Proportion of positive slides (% , # slides + / total slides):	No data	No data	No data	N/A
Cases diagnosed clinically (% , # clinical cases / total cases):	0% (0/2)	N/A	N/A	N/A
Percentage of cases with HIV-VL coinfection:	No data	N/A	N/A	N/A

N/A not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

## TREATMENT AND MEDICINES

- ▶ Is treatment provided for free in the public sector? (CL / VL): Yes / Yes
- ▶ Antileishmanial medicines included in the National Medicine List: Liposomal amphotericin B, Sodium stibogluconate (SSG)

## INITIAL TREATMENT OUTCOME FOR NEW CASES

	VL	ACL	ZCL
Cases that completed treatment (% , # completed treatment / new cases):	100% (2/2)	No data	No data
Initial cure rate (% , # cases initially cured / new cases):	100% (2/2)	No data	No data
Failure rate (% , # cases with treatment failure / new cases): <sup>4</sup>	0% (0/2)	No data	No data
Case fatality rate (% , # cases who died / new cases):	0% (0/2)	No data	No data

VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL = zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis

<sup>4</sup>Failure in this country is defined for VL as: "failure of improvement or deterioration during the treatment course" and for CL as: "Deterioration of clinical signs within the first 2 weeks, or absence of improvement after completion of treatment."